Neuronetics Inc (STIM) - Total Liabilities
Based on the latest financial reports, Neuronetics Inc (STIM) has total liabilities worth $108.38 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Neuronetics Inc to see how much of total assets are deployed in long-term investments.
Neuronetics Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Neuronetics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Neuronetics Inc's balance sheet.
Neuronetics Inc Competitors by Total Liabilities
The table below lists competitors of Neuronetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vistin Pharma ASA
OL:VISTN
|
Norway | Nkr103.25 Million |
|
Martin Midstream Partners LP
NASDAQ:MMLP
|
USA | $592.86 Million |
|
Big River Industries Ltd
AU:BRI
|
Australia | AU$145.90 Million |
|
Kyungin Synthe
KO:012610
|
Korea | ₩290.57 Billion |
|
Biotalys NV
BR:BTLS
|
Belgium | €9.18 Million |
|
Koryo Credit Information Co. Ltd
KQ:049720
|
Korea | ₩51.93 Billion |
|
Tomer Energy Royalties (2012) Ltd
TA:DLRL
|
Israel | ILA96.35 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Neuronetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Neuronetics Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.86 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuronetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuronetics Inc (2016–2025)
The table below shows the annual total liabilities of Neuronetics Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $115.31 Million | +5.69% |
| 2024-12-31 | $109.10 Million | +33.64% |
| 2023-12-31 | $81.64 Million | +36.47% |
| 2022-12-31 | $59.82 Million | +6.74% |
| 2021-12-31 | $56.05 Million | +5.42% |
| 2020-12-31 | $53.16 Million | +1.62% |
| 2019-12-31 | $52.32 Million | +13.78% |
| 2018-12-31 | $45.98 Million | -80.15% |
| 2017-12-31 | $231.59 Million | +14.69% |
| 2016-12-31 | $201.92 Million | -- |
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a p… Read more